Literature DB >> 9088590

The haemodynamic effects of subcutaneous sumatriptan, a 5HT1-receptor agonist.

S Hood1, D Birnie, S Hillis.   

Abstract

AIMS: Previous in vivo studies with sumatriptan, a 5HT1-receptor agonist, have demonstrated vasopressor responses in the pulmonary and systemic arterial circulation. Pulmonary artery wedge pressure (PAWP) also increases after sumatriptan injection, raising the possibility of an additional venoconstrictive action or a negative inotropic effect. The mechanism for the rise in PAWP was investigated in the study.
METHODS: Ten patients undergoing diagnostic coronary arteriography underwent haemodynamic monitoring.
RESULTS: There was a significant rise (P < 0.05) in systemic and pulmonary arterial pressure and total systemic and pulmonary vascular resistance. There was a similar rise (P < 0.05) in PAWP and left ventricular end diastolic pressure (LVEDP). There was no change in cardiac output nor in peak rate of left ventricular pressure rise (dP/dt).
CONCLUSIONS: The sumatriptan induced rise in PAWP and LVEDP appears consequent upon increased afterload although a negative inotropic effect cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088590      PMCID: PMC2042752          DOI: 10.1111/j.1365-2125.1997.00555.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Changes in systolic time intervals-a non-invasive marker for the haemodynamic effects of sumatriptan.

Authors:  S Hood; D Birnie; L S Murray; P D MacIntyre; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.

Authors:  Christopher M H Newman; Ian Starkey; Nigel Buller; Ricardo Seabra-Gomes; Simon Kirby; Jayasena Hettiarachchi; David Cumberland; William S Hillis
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

3.  The haemodynamic effect of the 5HT1 agonist BMS-180048: a class effect of triptans?

Authors:  L Swan; S Hood; D H Birnie; D F Muir; G P McCann; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.